These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 5822623)

  • 41. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
    Gangjee A; Adair O; Queener SF
    J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The synthesis of the dihydrofolate reductase inhibitors 2,4-diamino-5-substituted-benzylpyrimidines and their inhibition on L. casei DHFR and chicken liver DHFR].
    Fang ZX; Li RL; Jiang YM; Gao JN
    Yao Xue Xue Bao; 1988 Feb; 23(2):108-14. PubMed ID: 3188916
    [No Abstract]   [Full Text] [Related]  

  • 43. Active-site directed irreversible inhibitors of dihydrofolate reductase.
    Baker BR
    Ann N Y Acad Sci; 1971 Nov; 186():214-26. PubMed ID: 4943574
    [No Abstract]   [Full Text] [Related]  

  • 44. 2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
    Rosowsky A; Papoulis AT; Queener SF
    J Med Chem; 1997 Oct; 40(22):3694-9. PubMed ID: 9357537
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Irreversible enzyme inhibitors. CXL. Active-site-directed irreversible inhibitors derived from 1-(3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine.
    Baker BR; Lourens GJ
    J Med Chem; 1969 Jan; 12(1):95-101. PubMed ID: 5763050
    [No Abstract]   [Full Text] [Related]  

  • 47. Irreversible enzyme inhibitors. CLXXVII. Active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(phenylalkylphenyl)-s-triazines. II.
    Baker BR; Vermeulen NM
    J Med Chem; 1970 Nov; 13(6):1154-60. PubMed ID: 5479856
    [No Abstract]   [Full Text] [Related]  

  • 48. Irreversible enzyme inhibitors. CLXXIX. Active-site-directed irreversible enzyme inhibitors of dihydrofolate reductase from 1-(3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine with oxyamide bridges to a terminal sulfonyl fluoride.
    Baker BR; Ashton WT
    J Med Chem; 1970 Nov; 13(6):1165-70. PubMed ID: 5479858
    [No Abstract]   [Full Text] [Related]  

  • 49. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
    Robson C; Meek MA; Grunwaldt JD; Lambert PA; Queener SF; Schmidt D; Griffin RJ
    J Med Chem; 1997 Sep; 40(19):3040-8. PubMed ID: 9301666
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
    Gangjee A; Vasudevan A; Queener SF
    J Med Chem; 1997 Sep; 40(19):3032-9. PubMed ID: 9301665
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Irreversible enzyme inhibitors. CXXVII. p-(2,6-diamino-1,2-dihydro--2,2-dimethyl-s-triazin-1-yl)phenylpropionylsulfanilyl fluoride, an active-site-directed irreversible inhibitor of dihydrofolic reductase. 3. Effects of modification of the propionamide bridge on isozyme specificity.
    Baker BR; Luorens GJ
    J Med Chem; 1968 Jul; 11(4):666-72. PubMed ID: 5244344
    [No Abstract]   [Full Text] [Related]  

  • 52. Irreversible enzyme inhibitors. 178. Active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 1-(4-benzyloxy-3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine with a terminal sulfonyl fluoride.
    Baker BR; Ashton WT
    J Med Chem; 1970 Nov; 13(6):1161-5. PubMed ID: 5479857
    [No Abstract]   [Full Text] [Related]  

  • 53. Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
    Gangjee A; Lin X; Queener SF
    J Med Chem; 2004 Jul; 47(14):3689-92. PubMed ID: 15214795
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
    Gangjee A; Zhu Y; Queener SF; Francom P; Broom AD
    J Med Chem; 1996 Apr; 39(9):1836-45. PubMed ID: 8627607
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Irreversible enzyme inhibitors. 196. Active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 1-(4-benzyloxy-3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine and bearing a terminal phenyl sulfonate group.
    Baker BR; Ashton WT
    J Med Chem; 1972 Sep; 15(9):945-7. PubMed ID: 5051014
    [No Abstract]   [Full Text] [Related]  

  • 56. Irreversible enzyme inhibitors. CLXXVI. Active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine by ether bridging to a terminal sulfonyl fluoride.
    Baker BR; Ashton WT
    J Med Chem; 1970 Nov; 13(6):1149-54. PubMed ID: 5479855
    [No Abstract]   [Full Text] [Related]  

  • 57. Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
    Gangjee A; Elzein E; Queener SF; McGuire JJ
    J Med Chem; 1998 Apr; 41(9):1409-16. PubMed ID: 9554874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantitative correlation between molar refractivity and the inhibition of dihydrofolate reductase by 2,4-diamino-5-benzylpyrimidines.
    Kumar NA; Rao MN
    Indian J Biochem Biophys; 1986 Feb; 23(1):58-60. PubMed ID: 3525396
    [No Abstract]   [Full Text] [Related]  

  • 59. Irreversible enzyme inhibitors. 108. p-(4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazin-1-yl)phenylpropionylsulfanilyl fluoride, an active-site-directed irreversible inhibitor of dihydrofolic reductase. IV. Effects of substitution on the propionamide bridge on isozyme specificity.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jul; 11(4):672-7. PubMed ID: 5244345
    [No Abstract]   [Full Text] [Related]  

  • 60. Irreversible enzyme inhibitors. 173. Cure of Walker 256 ascites by reversible and irreversible inhibitors of dihydrofolic reductase derived from 1-(substituted-phenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine.
    Baker BR; Vermeulen NM; Ashton WT; Ryan AJ
    J Med Chem; 1970 Nov; 13(6):1130-40. PubMed ID: 5479852
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.